A recent study using AML cell lines and mouse models of FLT3 mutated AML suggests that Momelotinib-mediated combinatorial inhibition of JAK1/2, FLT3 and downregulation of MYC will be more effective than currently used FLT3 tyrosine kinase inhibitors (TKIs) [145]. This evidence concerns the gene JAK1 and acute myeloid leukemia.